Enclomiphene in Portland: What to Know Before You Try It

Enclomiphene is a selective estrogen receptor modulator (SERM) some men use to raise endogenous testosterone while preserving fertility. In Portland, it is typically prescribed through telehealth or men's-health clinicians for secondary hypogonadism. Unlike testosterone replacement therapy, it works upstream — signaling the pituitary to produce more LH and FSH so the testes make their own testosterone.

For Portland men weighing low-testosterone treatment options, enclomiphene comes up often, usually with one pitch: it can raise testosterone without the fertility cost of standard TRT. The clinical evidence is real but narrower than many men assume, and a thoughtful clinician frames it as one option among several.

What enclomiphene is and how it works

Enclomiphene is the trans-isomer of clomiphene citrate. Clomiphene itself has been around since the 1960s and is FDA-approved for female infertility under the brand name Clomid. The parent molecule is a mixture of two stereoisomers — enclomiphene (the trans-) and zuclomiphene (the cis-). Enclomiphene is the estrogen-receptor antagonist component; zuclomiphene is mildly estrogenic and has a much longer half-life.

In men, enclomiphene blocks estrogen receptors in the hypothalamus and pituitary. The brain reads the lower estrogen signal as "make more sex hormones," and responds by releasing more gonadotropin-releasing hormone (GnRH), which pushes up luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Higher LH stimulates Leydig cells in the testes to produce testosterone; higher FSH supports spermatogenesis.

That mechanism is the entire point. Standard TRT — gels, pellets, or weekly injections — supplies external testosterone, which suppresses the hypothalamic-pituitary-gonadal axis and reduces endogenous testosterone production along with fertility. Enclomiphene goes the other direction: it amplifies the body's own signal.

Enclomiphene is not FDA-approved as a standalone drug. The developer, Repros Therapeutics, sought approval under the brand name Androxal in 2015–2016, and the FDA declined, citing concerns about the trial design's clinical relevance. Today, men who receive enclomiphene in the United States typically obtain it through a compounding pharmacy with a prescription from a licensed clinician. The clinician-supervised enclomiphene program at Body Good Men walks through how that workflow looks for telehealth patients.

What the research actually shows

The most-cited human data comes from a phase II trial published in Fertility and Sterility (Wiehle et al., 2014), which compared enclomiphene to topical testosterone gel in 124 men with secondary hypogonadism. Both treatments raised total testosterone into the normal range. The key difference: men on testosterone gel saw their sperm counts crash, while men on enclomiphene maintained — and in some cases increased — sperm concentration and total motile sperm count.

A follow-up study in BJU International (Kim et al., 2016) tracked enclomiphene use in obese hypogonadal men over six months. Total testosterone rose from a baseline mean of roughly 250 ng/dL into the mid-normal range, while LH and FSH both increased and sperm parameters were preserved. Earlier work by Kaminetsky and colleagues in the Journal of Sexual Medicine (2013) reported a similar gonadotropin response across a dose-response arc.

A few honest caveats. First, the trials are small and short — months, not years. Long-term cardiovascular and bone-density outcomes have not been characterized in men the way they have for testosterone replacement (TRAVERSE trial, Lincoff et al., NEJM 2023). Second, trial populations skewed toward men with obesity-driven secondary hypogonadism; results may not generalize to primary testicular failure. Third, the AUA's 2018 testosterone-deficiency guideline lists enclomiphene as an option specifically for fertility-preserving treatment, not as a first-line agent for symptomatic hypogonadism in men who do not care about fertility.

How a Portland clinician evaluates a candidate

A clinician working through whether enclomiphene is appropriate will typically look at the same things their colleagues elsewhere do, with some local color. The standard workup:

• Two morning total testosterone levels, drawn between 7 and 10 a.m. on separate days. AUA guidelines call for two confirmatory low readings before diagnosing testosterone deficiency.
• LH, FSH, prolactin, SHBG, and free testosterone. A high-LH pattern points to primary testicular failure (where enclomiphene will not help much). A low-or-normal-LH pattern with low testosterone points to secondary hypogonadism (where the mechanism is most useful).
• Fertility plans. Men actively trying to conceive — or planning to within a few years — are typical candidates. So are men who want to keep that option open.
• Cardiometabolic baseline. BMI, lipids, hematocrit, A1c, blood pressure. Obesity-driven low testosterone often improves with weight loss alone.
• Symptoms and confounders. Obstructive sleep apnea, opioid use, chronic stress, and undertreated depression all suppress the HPG axis and can mimic hypogonadism.

The clinician — not the patient, and not the article — decides whether enclomiphene is a reasonable trial. Many Portland-area providers prefer to address modifiable contributors first.

Enclomiphene vs. testosterone replacement therapy

This is the comparison most men want, so it is worth being precise.

TRT (gel, injection, or pellet) supplies the hormone directly. It is the most reliable way to bring serum testosterone to a target range, has decades of safety data, and — based on the TRAVERSE cardiovascular outcomes trial — did not increase major adverse cardiac events in men with hypogonadism and elevated cardiovascular risk over a median follow-up of about 22 months. The tradeoff: HPG-axis suppression, smaller testes, and impaired spermatogenesis. For most men on TRT, fertility is significantly compromised within months.

Enclomiphene works upstream. Trial data show it can raise testosterone into the normal range in men with secondary hypogonadism while keeping LH, FSH, and sperm production intact. The tradeoff: response is more variable than TRT, the long-term outcomes data is thinner, and not every pituitary responds adequately. The honest summary a clinician might offer is that TRT is a more powerful, better-characterized lever but costs fertility while you are on it; enclomiphene is a gentler nudge that preserves fertility, with a narrower evidence base. Patients who want to read more about clinician-supervised options can review the men's hormone education at Body Good Men.

Local lifestyle factors worth flagging

Portland's environment shapes a few inputs to testosterone that often go unmeasured:

Vitamin D status. The Pacific Northwest gets 35–40% fewer sunny days than the national average, and several observational studies have linked low 25-hydroxyvitamin D with lower total testosterone (Pilz et al., Hormone and Metabolic Research, 2011). It is worth measuring before assuming hypogonadism is structural.

Endurance training volume. Portland has one of the highest per-capita rates of recreational cycling and trail running in the country. Sustained high-volume endurance work — particularly on a calorie-restricted diet — is associated with lower testosterone in some men. A clinician will want to know the volume profile.

Sleep and screen time. Long winters and indoor evenings push back light exposure and bedtime, which compresses sleep duration and quality. Both correlate strongly with morning testosterone.

None of these mean enclomiphene is the wrong choice. They mean the workup should look at the whole picture before adding a medication.

Common misconceptions

A few patterns worth correcting:

• "Enclomiphene is the same drug as Clomid." It is a single isomer of the molecule in Clomid. The pharmacology overlaps, but the side-effect profile differs because zuclomiphene is largely absent.
• "Enclomiphene is FDA-approved for men." It is not. Clomiphene citrate is approved for female infertility; enclomiphene as a standalone drug is not approved for any indication and is typically obtained through compounding.
• "It will work as fast as TRT." Most men see meaningful lab changes over weeks, not days, and symptomatic improvement often lags the lab change.

The Body Good Men enclomiphene workflow outlines what eligibility review and lab monitoring look like for a telehealth patient.

Frequently asked questions

What does enclomiphene do in men?

Enclomiphene blocks estrogen receptors at the hypothalamus, which causes the pituitary to release more LH and FSH. The result is increased endogenous testosterone production with preserved spermatogenesis. It is used in some men with secondary hypogonadism — low testosterone driven by under-signaling from the brain rather than testicular failure — particularly when fertility preservation matters.

Is enclomiphene FDA-approved?

No. Enclomiphene is not FDA-approved as a standalone drug for any indication. Clomiphene citrate, the racemic mixture that contains enclomiphene, is approved only for female infertility. In the United States, men who receive enclomiphene typically do so through a compounding pharmacy with a prescription from a licensed clinician who has determined it is appropriate for their case.

How long does enclomiphene take to work?

Lab markers — LH, FSH, total testosterone — typically begin shifting within two to four weeks of starting therapy, with a fuller response by eight to twelve weeks. Symptomatic improvement often trails the lab change. A clinician will usually recheck labs at a defined interval and adjust the plan based on response, lab values, and tolerability.

Can enclomiphene affect fertility?

Published trial data suggest enclomiphene preserves and in some cases increases sperm parameters, in contrast to standard testosterone replacement, which suppresses them. That is the principal reason it is prescribed in men who want to maintain fertility. Individual response varies, and a clinician monitoring a man with active fertility goals will typically include a semen analysis in the workup.

Is enclomiphene safer than TRT?

"Safer" is the wrong frame. Enclomiphene has a different risk profile from testosterone replacement. TRT has decades of outcomes data including the TRAVERSE cardiovascular trial; enclomiphene has smaller, shorter trials and limited long-term safety evidence. The right question for a clinician is which option fits a specific man's goals, lab profile, and timeline.

---

If you are considering whether enclomiphene may be appropriate for your situation, talk to a licensed clinician. The Enclomiphene program at Body Good Men connects you with a US-licensed clinician who reviews your eligibility and, if appropriate, prescribes through our partner pharmacy.

---

Important Disclosure

men.joinbodygood.com is operated as an affiliate of Body Good Studio LLC and is a whitelabel certified partner of Leg Up Rx. men.joinbodygood.com does not provide medical services, prescribe medications, or maintain patient records. All clinical evaluations, prescription decisions, and medication fulfillment are handled by licensed medical and pharmacy partners through Leg Up Rx. This article is for general informational purposes only and is not medical advice. Talk to a licensed healthcare provider before starting any treatment. Eligibility for any medication is determined solely by a licensed clinician.

---